Form 4: Denali Therapeutics Director Vicki L. Sato Sells Shares Under 10b5-1 Trading Plan

Director Vicki L. Sato of Denali Therapeutics Inc. reported selling 1,020 shares of common stock at $30 per share on November 7, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On November 7, 2024, Vicki L. Sato, a director of Denali Therapeutics Inc., sold 1,020 shares of common stock.
• The sale was executed at a price of $30 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 21, 2024.
• Following the transaction, Sato beneficially owns 111,056 shares of Denali Therapeutics Inc., which includes 5,967 unvested Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine stock sale under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on material non-public information. The market typically views these sales in the context of the overall insider ownership and the reasons behind the selling activity.

Comparison to Industry Standards

• Insider sales are a regular part of corporate governance, especially in publicly traded companies like Denali Therapeutics.
• Rule 10b5-1 plans are widely used by executives and directors at companies like Amgen, Biogen, and Gilead to manage their stock sales in compliance with SEC regulations.
• The volume of shares sold is relatively small compared to the total outstanding shares of Denali Therapeutics, which is typical for routine insider sales.

Stakeholder Impact

• The sale of shares by a director could have a minor psychological impact on shareholders, but is unlikely to have a significant material impact given the relatively small size of the transaction and the use of a 10b5-1 trading plan.

Key Dates